Laurus Labs is lined up to copy 3 of the blockbuster drugs on this tracker, which earned $24.3B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Laurus Labs' stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | FDA-approved 28 May 2024; first filer; FDA has not decided whether it keeps 180-day shared exclusivity | $7.7B |
| Opsumit | Johnson & Johnson | Generic | 2026 | FDA-approved 5 Nov 2025 | $2.3B |
| Biktarvy | Gilead | Generic | 2036 | Filed with the FDA; settled Oct 2025; US entry allowed from 1 Apr 2036. Subject to standard acceleration provisions | $14.3B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Laurus Labs' share of it.
Laurus Labs has FDA approval for Entresto and Opsumit, with no US launch confirmed; and applications filed for Biktarvy. It has settled with the brand owner over 1 drug. Of the 70 makers we follow, 25 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.